MetaboLightsapplication/xmlftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14417/m_MTBLS14417_LC-MS_alternating_hilic_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14417/i_Investigation.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14417/s_MTBLS14417.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14417/a_MTBLS14417_LC-MS_alternating_hilic.txtprimaryOK200ftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS14417<p>LC-MS data were processed with MS-Dial 4.9.2, which facilitated compound identification through accurate mass measurements and MS2 spectra. For identification purposes an in house metabolite retention time library was utilised. The Compounds were subjected to statistical evaluation with MetaboAnalyst. This involved the application of Pareto scaling, alongside both univariate and multivariate statistical techniques, including Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA).</p>MetaboLightsPublic<p>Mass spectrometric detection was achieved by coupling the liquid chromatography system with a Thermo Orbitrap Q Exactive Plus mass spectrometer. The HESI II ion source was utilised for ionisation in both positive and negative modes. MS parameters were meticulously optimised, covering scan ranges of 70–1,050 m z-1 with a resolution of 35,000 for full scans, and 17,500 resolution for data-dependent MS2 acquisitions.&nbsp;</p>Liquid Chromatography MS - alternating - hilic<p>The chromatographic separation was performed using an Agilent 1290 Infinity II Bio LC system equipped with an AdvanceBio MS Spent Media column (150 x 2.1 mm, 2.7 μm). A gradient elution was implemented at a flow rate of 450 μl min-1, where solvent A was water containing 10 mM ammonium acetate (pH 9), and solvent B was a mixture of acetonitrile and water (95:5 v/v) with the same ammonium acetate concentration. The linear gradient profile was as follows: 0 min, 100% B; 0.5 min, 100% B; 6.5 min, 50% B; 7 min, 50% B; 7.01 min, 100% with 1.1 minutes equilibration between the runs. The column temperature was consistently maintained at 70 °C, with a sample injection volume of 1 μl.&nbsp;</p>Reverse engineering of BNIP3 identifies a mitochondrial protective peptide.Sebastian KorsteUniversity Hospital Essen - Clinic for Cardiology and Vascular Medicineheart tissuemass spectrometry assay<p>Metabolites were extracted using a two-step liquid method similar to Sellik et al.90. Internal standards (13C6-L-Arginine, 13C5-L-Valine, 13C2-Citric acid, 2H4-Succinic acid and 13C6-Fructose-6-phosphate) were added, followed by homogenisation, sonication, and centrifugation. Supernatants were collected, dried, and resuspended.</p>Mus musculushttps://www.ebi.ac.uk/metabolights/MTBLS14417Ulrike Hendgen-Cotta. University Hospital Essen - Clinic for Cardiology and Vascular Medicine. Hufelandstrasse 55, 45147 Essen, Germany. ulrike.hendgen-cotta@uk-essen.de.<p>LC-MS data were processed with MS-Dial 4.9.2, which facilitated compound identification through accurate mass measurements and MS2 spectra. For identification purposes an in house metabolite retention time library was utilised. The Compounds were subjected to statistical evaluation with MetaboAnalyst. This involved the application of Pareto scaling, alongside both univariate and multivariate statistical techniques, including Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA).</p><p>LC-MS data were processed with MS-Dial 4.9.2, which facilitated compound identification through accurate mass measurements and MS2 spectra. For identification purposes an in house metabolite retention time library was utilised. The Compounds were subjected to statistical evaluation with MetaboAnalyst. This involved the application of Pareto scaling, alongside both univariate and multivariate statistical techniques, including Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA).</p>ControlPEPBSham24hTreated60minI/RPEPCsebastian.korste@uk-essen.de<p>For global metabolomic analysis by liquid chromatography-tandem mass spectrometry (LCMS/MS), heart fragments weighting 30–70 mg were homogenised using an&nbsp;electronic tissue disruptor (Qiagen) in ice-cold methanol. </p>MetabolomicsMetabolomicsThermo Scientific LTQ OrbitrapMus musculusuntargeted analysismyocardial infarctionMS-DIALdata-dependent acquisitionheart tissueAgilent 1290 Infinity 2D-LCexperimental sampleMetabolomicsMus musculusThermo Scientific LTQ Orbitrapuntargeted analysismyocardial infarctionMS-DIALdata-dependent acquisitionAgilent 1290 Infinity 2D-LCheart tissueexperimental sample<p>Mass spectrometric detection was achieved by coupling the liquid chromatography system with a Thermo Orbitrap Q Exactive Plus mass spectrometer. The HESI II ion source was utilised for ionisation in both positive and negative modes. MS parameters were meticulously optimised, covering scan ranges of 70–1,050 m z-1 with a resolution of 35,000 for full scans, and 17,500 resolution for data-dependent MS2 acquisitions.</p>falseMetabolomics of heart tissue at baseline and following myocardial infarctionA comprehensive analysis of the heart metabolome was conducted at 60 min reperfusion post ischaemia. This analysis employed LC-MS/MS in order to provide a detailed examination of the metabolic processes occurring within the heart. The focus of this analysis was placed on glycolysis, the tricarboxylic acid (TCA) cycle, and amino acid metabolism. An increase in the level of the glycolytic end product lactate was observed under treatment compared with the sham and control groups, which is in accordance with the recent findings that in ischaemia/reperfusion injury targeting the pyruvate-lactate metabolism by inhibiting lactate export could be a promising protective therapy. The principal TCA cycle intermediates elevated in the treatment group relative to the control and sham groups were succinate, fumarate, malate, and the TCA cycle overall rate-determining intermediate α-ketoglutarate. In a similar manner, the amino acid metabolism, which is influenced by TCA cycle dysfunction, was regulated by our treatment, as evidenced by elevated levels of proline, serine, and asparagine in comparison to the non-treated and sham groups. Given the close coupling between TCA cycle activity and myocardial contractile function, and the development of LV dysfunction following I/R injury, the elevation of TCA cycle intermediates and amino acid levels observed within the treatment group may reflect a compensatory metabolic response that contributes to preserved contractile function, as supported by enhanced ATP generation under treatment.2026-04-302026-04-30MTBLS14417